

Citation for published version:

Lawn, W, Hill, J, Hindocha, C, Yim, J, Yamamori, Y, Jones, G, Walker, H, Green, SF, Wall, MB, Howes, OD, Curran, HV, Freeman, TP & Bloomfield, MAP 2020, 'The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers', *Journal of Psychopharmacology*, vol. 34, no. 9, pp. 969-980. <https://doi.org/10.1177/0269881120944148>

DOI:

[10.1177/0269881120944148](https://doi.org/10.1177/0269881120944148)

Publication date:

2020

Document Version

Peer reviewed version

[Link to publication](#)

Lawn, Will ; Hill, James ; Hindocha, Chandni ; Yim, Jocelyn ; Yamamori, Yumeya ; Jones, Gus ; Walker, Hannah ; Green, Sebastian F. ; Wall, Matthew B. ; Howes, Oliver D. ; Curran, H. Valerie ; Freeman, Tom P. ; Bloomfield, Michael A.P. / The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. In: *Journal of Psychopharmacology*. 2020 ; Vol. 34, No. 9. pp. 969-980. (C) SAGE Publications. Reproduced by permission of SAGE Publications.

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Title page

Title

The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers

Authors

Will Lawn^{1*}, James Hill^{2*}, Chandni Hindocha^{1,2,3}, Jocelyn Yim², Yumeya Yamamori^{2,4,5}, Gus Jones², Hannah Walker², Sebastian F. Green², Matthew M. Wall^{1,6}, Oliver Howes⁷, H. Valerie Curran^{1,3}, Tom P. Freeman^{1,2,8,9} & Michael A.P. Bloomfield^{1,2,3,7,10,11}

1 Clinical Psychopharmacology Unit, Division of Psychology and Language Sciences, University College London, 1-19 Torrington Place, London, United Kingdom.
2 Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, United Kingdom.
3 NIHR University College London Hospitals Biomedical Research Centre, University College Hospital, London, United Kingdom.
4 Institute of Cognitive Neuroscience, University College London, London, United Kingdom
5 Department of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.
6 Invicro London, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, London, United Kingdom.
7 Psychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom.
8 Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, United Kingdom.
9 National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, London, United Kingdom.
10 The Traumatic Stress Clinic, St Pancras Hospital, Camden and Islington NHS Foundation Trust, London, United Kingdom.
11 National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.

*These authors contributed jointly to the research

37 **Short-title**

38 CBD's acute effects on neural correlates of reward

39

40 **Keywords**

41 Cannabidiol, reward, fMRI, motivation, anticipation, feedback, cannabis, marijuana

42

43 **Corresponding author**

44 Dr Will Lawn

45 Email: will.lawn@ucl.ac.uk

46

47 Clinical Psychopharmacology Unit

48 Psychology and Language Sciences

49 University College London

50 1-19 Torrington Place

51 London

52 WC1E 7HB

53

54

55 Word count (main text): 5393

56 Word count (abstract): 244

57 Number of tables: 4

58 Number of figures: 3

59

60

61 **Funding**

62 This study was funded by a British Medical Association Foundation for Medical Research Margaret
63 Temple Award to Dr Bloomfield. Dr Bloomfield is funded by a UCL Excellence Fellowship. Dr
64 Lawn is funded by an unrelated Medical Research Council project grant. Drs Bloomfield and
65 Hindocha and Professor Curran are supported by the National Institute for Health Research University
66 College London Hospitals Biomedical Research Centre. Dr Freeman was funded by a senior academic
67 fellowship from the Society for the Study of Addiction. Dr Wall is employed by Invicro LLC, a
68 private company which performs contract research work for the pharmaceutical and biotechnology
69 industries.

70

71 **Declarations of conflicts of interest**

72 The authors declare no conflicts of interest.

Abstract

Background

Cannabidiol (CBD) has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that CBD may influence some aspects of reward processing. However, it is unknown whether CBD acutely affects brain function underpinning reward anticipation and feedback.

Hypotheses

We predicted that CBD would augment brain activity associated with reward anticipation and feedback.

Methods

We administered a single 600mg oral dose of CBD and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay (MID) task during functional magnetic resonance imaging (fMRI) to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest (ROI) analyses in pre-specified reward-related brain regions.

Results

The MID task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate, and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that CBD altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our

ROIs was similar following CBD and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between CBD and placebo.

Discussion

CBD did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of CBD on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders.

Introduction

Reward processing refers to the neural, psychological and behavioural processes that underpin the seeking and consumption of rewards (Berridge et al., 2009). The human brain reward system is made up of key regions such as the ventral tegmental area (VTA), ventral and dorsal striatum, anterior cingulate cortex, the orbitofrontal cortex, ventral pallidum, amygdala, insula, thalamus and parahippocampal regions (Haber and Knutson, 2010; Knutson and Greer, 2008). Fronto-striatal loops pass reward-related information from the prefrontal cortex to subcortical regions and back again, such that organisms can orient attention to, be motivated for, and consume rewards (Haber and Knutson, 2010).

Reward processing is perturbed in a variety of psychiatric disorders, including depression (Eshel and Roiser, 2010; Knutson, Wimmer, et al., 2008; Whitton et al., 2015), addiction (Balodis and Potenza, 2015; Goldstein and Volkow, 2011) and schizophrenia (Gold et al., 2008; Juckel et al., 2006; Strauss et al., 2013). Dysfunctional reward processing therefore represents an important transdiagnostic neurocognitive mechanism which may contribute to the emergence of various psychiatric disorders (Husain and Roiser, 2018; Insel, 2010; Whitton et al., 2015). Hence, the reward circuit is a potential target for novel psychiatric drug treatments. Successful manipulation of the reward system could lead to the amelioration of impaired reward learning, motivation and pleasure, observed across various clinical diagnoses.

The endocannabinoid system plays an important role in modulation of the brain's reward processes (Bloomfield et al., 2016; Parsons and Hurd, 2015; Solinas et al., 2009). CB1 receptors are expressed at a moderate level at the origin of the mesolimbic dopamine pathway, the VTA, and at a higher level at the terminal region, the nucleus accumbens (NAcc) (Curran et al., 2016; Solinas et al., 2009).

Cannabidiol (CBD) is the second most abundant cannabinoid in the cannabis plant (Upton et al., 2014; Pertwee, 2008) and at typical doses CBD is non-intoxicating (Haney et al., 2016; Hindocha et al., 2015; Lawn et al., 2016; Martin-Santos et al., 2012). CBD has therapeutic potential in a variety of psychiatric disorders (Freeman et al., 2019; Khan et al., 2020). Preclinical research has demonstrated that CBD administration can affect reward-related behaviours, particularly reducing drug-seeking behaviour (Hay et al., 2018; Katsidoni et al., 2013; Parker et al., 2004; Ren et al., 2009; Schier et al., 2014; Viudez-Martínez et al., 2018). Speculatively, CBD could ameliorate addictive behaviour by enhancing the sensitivity of the reward system to natural rewards, such that pharmacological rewards are less desired. The effects of CBD on the mesolimbic dopamine system are, however, equivocal (Renard et al., 2017).

Human research has shown that CBD can acutely alter neural, behavioural and psychological processes relating to reward, including effort sensitivity (Lawn et al., 2016), attentional bias to drug pictures (Hindocha et al., 2018; Morgan et al., 2010), drug consumption (Freeman et al., in press; Morgan et al., 2013), neural response to music reward (Freeman et al., 2018) and levels of stress-induced social anxiety (Bergamaschi et al., 2011; Zuardi et al., 1993), without producing reinforcing or unpleasant side-effects (Haney et al., 2016). However, it is not known if CBD specifically acts on the human brain's reward circuitry, or acts by another mechanism. Furthermore, if CBD does act on the reward system, its effects on reward anticipation and reward feedback have not been parsed.

The monetary incentive delay (MID) task is a well-validated functional magnetic resonance imaging (fMRI) task which, through its structure, allows for investigation of the neural

correlates of reward anticipation and reward feedback (Balodis and Potenza, 2015; Knutson et al., 2001). Meta-analyses of MID task results show reward anticipation and feedback recruit overlapping and distinct regions (Knutson and Greer, 2008; Oldham et al., 2018). Both processes activate striatal regions, while reward anticipation activates the thalamus and insula, and reward feedback preferentially activates prefrontal cortex areas. Importantly, neural activity during reward anticipation in the ventral striatum correlates with dopamine release in the same region (Schott et al., 2008), demonstrating the task engages the mesolimbic dopamine system.

CBD seemingly has opposite effects to the primary intoxicating cannabinoid found in cannabis, delta-9-tetrahydrocannabinol (THC), on both brain and behavioural outcomes (Bhattacharyya et al., 2010; Bloomfield et al., 2016; Englund et al., 2013). CBD enhanced striatal activation during a verbal memory task, while THC dampened striatal activity (Bhattacharyya et al., 2010). In the MID task, acute THC administration has been shown to attenuate the widespread neural response to reward feedback (van Hell et al., 2012) and attenuate the neural response in the nucleus accumbens during reward anticipation in people with nicotine dependence (Jansma et al., 2013). Therefore, one might expect CBD to do the opposite: augment neural response to reward anticipation and feedback. Furthermore, a pro-reward function action could underlie CBD's putative anti-addiction, anti-depressant and anxiolytic effects.

In summary, the endocannabinoid system plays an important role in the brain's reward circuitry and both preclinical and human research has demonstrated that CBD can modulate reward-related behaviours. However, previous human studies have tended to investigate CBD's impact alongside THC. Moreover, they have focused on psychiatric symptom-based measures, rather than precise components of reward processing, such as anticipatory and consummatory reward

processes which are indexed by the well-validated MID task. No study has examined the specific, isolated effect of CBD on the human brain during reward processing. Based on its opposing effects to THC and its ostensibly therapeutic effects in disorders characterised by reward dysfunction, we predicted that CBD would augment the neural response to reward anticipation and feedback.

Methods

Design and participants

The study used a double-blind, randomized, placebo-controlled, repeated-measures design to compare the effects of oral CBD 600mg with matched placebo (PBO). Drug order was balanced and randomised. Drug order was completely concealed from participants and concealed from experimenters until data collection, entry, and analysis had been completed.

We tested 28 healthy participants. Four participants did not complete both sessions, so they were excluded. Furthermore, one participant did not complete the MID task correctly, so they were excluded. That left 23 participants in our analysis.

Participants were recruited through public advertisement. Inclusion criteria were: (1) age 18-70 years; (2) right-handed; (3) fluent in English. Exclusion criteria were: (1) positive urine screen for recreational drug use (Alere Toxicology UC-10A; amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, morphine, methadone, phencyclidine, tricyclic antidepressants, THC), (2) recent (within the past six months) use of any psychotropic (recreational or medical) drug, including cannabis, (3) positive breath test for alcohol, (4) carbon monoxide ≥ 5 parts per million (ppm), (5) problematic alcohol use, as defined by a score ≥ 8 on the Alcohol Use Disorder Identification Test (AUDIT) (Saunders et al., 1993), (6) more than ten lifetime uses of cannabis or CBD, (7) more than five lifetime uses of any other recreational drug, (8) nicotine dependent, as defined by a score greater than three on Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991), (9) current or past mental or physical health issues or learning impairments, based on an adapted version of the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) Structured Clinical Interview (SCID) (Gibbon and Spitzer, 1997), (10) positive reading on urine pregnancy test,

(11) breast-feeding, (12) known allergies or aversions to CBD, microcrystalline cellulose, gelatine or lactose, (13) colour blindness, (14) MRI contraindications, (15) current use of psychiatric medications.

Participants were reimbursed £10/hour for their time. This study was approved by the UCL ethics committee (Project Number: 3325/002), and all participants provided written informed consent.

Assessments

The Monetary Incentive Delay (MID) task (Knutson et al., 2000) (Figure 1)

The MID task is a well-validated task that allows measurement of neural activity during reward anticipation and reward feedback using functional magnetic resonance imaging (fMRI). We used an adapted version of the original (Knutson et al., 2000).

In our version of the task, a cue (a square) is first presented for 500ms, which signals whether the trial is a win trial (if the square is orange) or a neutral trial (if the square is blue). On a win trial, the participant has the opportunity to win 30p if they respond to a subsequent target in time. On a neutral trial, the participant cannot win or lose any money, but they are asked to respond to the subsequent target as quickly as they can anyway. Following the cue, there is a blank screen, the anticipation phase, for 2-4s in which the participant waits for the target. Subsequently, the target (a white square) is presented and the participant must respond to it as quickly as they can by pressing a button with their thumb on their right hand. Initially, participants must respond to the target within 300ms in order to get a ‘hit’. However, following a successful ‘hit’, the next trial’s target must be responded to within a time that is 16.67ms shorter than the previous trial in order to get another ‘hit’. Following a ‘miss’, the next trial’s

target must be responded to within a time that is 16.67ms longer than the previous trial in order to get a 'hit'. This is to calibrate the participant's performance to 'hit' roughly 50% of the time. Following the target, feedback is presented for roughly 1000ms (although this changes on a trial-by-trial basis along with changes in target duration). If it is a 'win' trial and the participant gets a 'hit', then the participant wins 30p and is told 'Hit. You win 30p'. If it is a 'win' trial and the participant gets a 'miss', then the participant does not win money and is told 'Miss'. If it is a 'neutral' trial and the participant gets a 'hit', then the participant does not win money and is told 'Hit'. If it is a 'neutral' trial and the participant gets a 'miss', then the participant does not win money and is told 'Miss'. The current total won is always displayed on the feedback screen. Following the feedback, there is an inter-trial interval (ITI) between 1.2 and 9.2s when a blank screen is shown.

There are 48 trials in total, of which 24 are neutral trials in which no money can be earned and 24 are win trials in which money can be earned. The order of win trials was fixed, so that win trials did not appear consecutively. Each win trial provides the opportunity to win 30p; this amount does not vary, as in some previous MID task versions (Knutson et al., 2008). There are also no loss trials. The task lasts for 12 minutes.

The MID task produces measures of brain activity associated with reward anticipation and reward feedback. It also produces behavioural measures of mean reaction time to respond to the target on successful 'win' and 'neutral' trials and the proportion of 'hits' on 'win' and 'neutral' trials.

[Insert Figure 1]

262 *Demographics*

263 We recorded participants' age, sex, weight and BMI.

264

265 *Beck Depression Inventory (BDI) (Beck et al. 1996)*

266 A self-reported scale of depression severity which consists of 21 items. This measured the

267 participants' depressive symptomatology over the preceding two weeks to the first study visit.

268 Higher scores reflect a higher severity of depression.

269

270 *Alcohol Use Disorder Identification Test (AUDIT) (Saunders et al., 1993)*

271 A self-reported scale which screens for problematic alcohol use and consists of 10 items. Scores

272 range from 0 to 40, with higher scores reflecting more severe problematic alcohol use. A score

273 of 8 or more is considered hazardous.

274

275 *Fagerstrom Test for Nicotine Dependence (FTND) (Heatherton et al., 1991)*

276 A self-reported scale of nicotine dependence consisting of six items. Total scores range from 0

277 to 10, with higher scores reflecting higher nicotine dependence.

278

279 *Wechsler Test for Adult Reading (WTAR) (Ginsberg et al., 2003)*

280 A test of reading ability which is a proxy of verbal intelligence. It includes 50 words that must

281 be read aloud and pronounced correctly.

282

283 *Plasma CBD levels*

284 Blood samples were collected using EDTA vacutainers and centrifuged immediately. Plasma

285 samples were stored at -80°C prior to analysis. CBD concentrations were determined using gas

286 chromatography mass spectroscopy (GC/MS) with a lower limit of quantification of 0.5mg/ml.

287

288 Drug Administration

289 Participants were administered a single dose of 600mg oral CBD (pure synthetic (-)-CBD, STI
290 Pharmaceuticals, Essex, England) or matched placebo (lactose powder) in identical, opaque
291 capsules on each testing session. The CBD was formulated in 50mg capsules. Participants
292 swallowed all 12 capsules at their own pace under invigilation of the experimenter. 600mg was
293 chosen as it produces an increase in plasma concentrations after acute administration
294 (Babalonis et al., 2017; Englund et al., 2013), is well tolerated in humans (Grotenhermen et al.,
295 2017), produces a significant anxiolytic effect (Bergamaschiet al., 2011), produces opposing
296 effects to THC on the striatum as assessed by fMRI (Bhattacharyya et al., 2010), and elicits
297 anti-psychotic like effects in combination with THC (Bhattacharyya et al., 2015).

298

299 Procedure

300 Participants completed a screening on the telephone during which initial eligibility criteria
301 (drug use, FTND, AUDIT, MRI contraindications, allergies, medical information, and
302 handedness) were assessed and basic participant details were recorded. Participants that
303 appeared eligible on the phone were invited to attend experimental sessions. Participants were
304 asked to fast from midnight the day before both sessions, and refrain from smoking tobacco
305 and consuming alcohol for 24 hours before the start of the sessions. Upon arrival, participants
306 underwent urine tests to verify they were not pregnant (if female) and they had not recently
307 taken recreational drugs. They also completed breath tests for alcohol and carbon monoxide.

308

309 Eligible participants then completed two seven-hour experimental sessions, when they received
310 CBD or PBO on the first session, and the other drug condition on the second session.
311 Experimental sessions were separated by a minimum seven-day wash-out period (>4 times the

elimination half-life) to minimize carryover effects of CBD (Consroe et al., 1991). The BDI and WTAR were completed immediately after drug administration on the second session. Previous research suggests that CBD reaches the peak level of plasma concentration after approximately 2.5 hours (Babalonis et al., 2017). Therefore, 2.5 hours after drug administration, participants underwent MRI scanning for 1.5 hours to complete the MID task, as well as other tasks and scans, which will be reported elsewhere. Participants' blood samples were taken straight after the scan finished, which was approximately 4 hours and 15 minutes after drug administration. After a standardised lunch provided by the experimenter, participants completed a series of questionnaires and computer tasks, results of which will be reported elsewhere.

Power calculation

A power calculation was conducted using G*Power (version 3.1.9.2). This showed that a sample size of 20 would have 81% power to detect a significant ($p < 0.05$, two-tailed) difference between CBD and placebo (PBO) with a moderate or greater effect size of $d = 0.5$. This effect size was based on the previous finding of the difference in the attentional bias toward cigarette cues between 800mg CBD vs. placebo in nicotine-dependent users (Hindocha et al., 2018). We then recruited extra participants to account for expected participant dropout and exclusions.

MRI data acquisition

MRI data was collected using a 3-Tesla Siemens Verio MRI Scanner at the Robert Steiner MR unit at Hammersmith Hospital, London. Functional imaging used a multiband (acceleration factor = 2) gradient-echo T2*-weighted echo-planar imaging (EPI) sequence with 42 slices per volume (TR = 2400ms; TE = 30ms; in-plane matrix = 64 x 64; 3mm isotropic voxels; flip angle = 62°; bandwidth = 1594 Hz/pixel; 304 volumes; a slice thickness of 3mm; field of view =

192mm x 192mm). The phase encoding direction was from anterior to posterior. Echo spacing was 0.71ms. There were 3 dummy scans at the beginning of the scan, which were not included in our dataset. For structural acquisition, a T1-weighted structural volume was acquired for all participants using a Magnetisation Prepared Rapid Gradient Echo (MPRAGE) scan (TR = 2300ms; TE = 2.28ms, TI= 900ms, flip angle = 9°, field of view= 256mm, image matrix = 256 with 1-mm isotropic voxels; bandwidth = 200 Hz/pixel).

Functional magnetic resonance imaging (fMRI) data analyses

Image pre-processing and analysis were performed using FSL's fMRI Expert Analysis Tool (FEAT) (FMRIB Software Library v6.0, Analysis Group, FMRIB, Oxford, UK) (Jenkinson et al., 2012). Data were pre-processed before being subject to first and second-level analyses.

Pre-processing

FSL's brain extraction tool (BET) was used to strip the brain from the skull. FMRIB Automated Segmentation Tool was used to separate out grey matter, white matter, and cerebrospinal fluid. Functional images were realigned to the middle volume using FSL's MCFLIRT procedure, in order to correct for head motion. Subsequently, the functional images were co-registered to the individual participant's structural image and normalised to the MNI-152 (Montreal Neurological Institute) template using FEAT's non-linear transformation procedure with a 10mm warp resolution. An isotropic 6mm full-width at half-maximum Gaussian kernel (i.e. twice the voxel size) was then applied to spatially smooth images. A high-pass filter (100s cut-off) was applied to remove low-frequency noise. Images were visually inspected to ensure that the pre-processing had worked correctly.

361 T₁-weighted structural images were also skull-stripped with FSL's BET and normalised to the
362 MNI-152 template.

363

364 *First level analyses*

365 Timestamps and durations for each event (cue, anticipate, target, feedback, inter-trial-interval)
366 in the MID task were extracted from the task output files using scripts written in Matlab
367 (Mathworks Inc., United States). A general linear model was created with the following
368 explanatory variables (i.e. regressors): (1) reward anticipation (i.e. anticipate-win), (2) no
369 reward anticipation (i.e. anticipate-neutral), (3) reward feedback on a successful win trial (i.e.
370 feedback-win-hit), (4) no reward feedback on an unsuccessful win trial (i.e. feedback-win-
371 miss), (5) no reward feedback on a successful neutral trial (i.e. feedback-neutral-hit), (6) no
372 reward feedback on an unsuccessful neutral trial (i.e. feedback-neutral-miss). Each event was
373 modelled with a boxcar function with the event's duration convolved with the canonical
374 haemodynamic response function, using the gamma function. Extended motion parameters and
375 temporal derivatives were included as additional regressors-of-no-interest.

376

377 These contrasts were then calculated:

378 (1) 'reward anticipation': anticipate-win > anticipate-neutral.

379 (2) 'reward feedback': feedback-win-hit > feedback-neutral-hit.

380

381 *Second level analyses*

382 *Whole brain analysis*

383 The second-level fMRI data analysis was also performed with FSL's FEAT pipeline (Jenkinson
384 et al., 2012), using a random effects analysis with FMRIB's Local Analysis of Mixed Effects

(FLAME). We analysed the two contrasts specified above at the second level. We used clusterwise correction, with a cluster-defining threshold of $z=2.3$ and an alpha value of 0.05. We conducted one-sample t-tests for both contrasts, collapsing across both drug conditions, to investigate the overall effect of the task (reward anticipation and reward feedback) on brain activity. Secondly, we conducted paired t-tests for both contrasts to investigate the differences, in both directions, between CBD and PBO.

Region of interest (ROI) analyses

ROIs were pre-specified based on a meta-analysis of MID fMRI results for significantly activated regions for reward anticipation and feedback (Knutson and Greer, 2008). There were eight ROIs for anticipation and seven ROIs for feedback, as shown in Table 1. The Talairach coordinates from Knutson and Greer (2008) were converted to MNI coordinates using the mni2tal MATLAB function created by the University of Cambridge Medical Research Council Cognition and Brain Sciences Unit (<http://imaging.mrc-cbu.cam.ac.uk/imaging/MniTalairach>). We used these coordinates as the centres for our spherical ROIs, with radii of 5mm. The ROIs were created using FSLeyes and fslmaths functions. We then extracted average unstandardized beta values (with arbitrary units) from these regions for the two contrasts described above.

We then ran one-sample t-tests (against a score of zero) to test whether the task elicited the expected anticipation and feedback activation in the hypothesised regions. Subsequently, we ran paired t-tests for an effect of drug (CBD vs. PBO) on the activation in these anticipation and feedback ROIs. We reduced the alpha value to 0.006 to account for the multiple tests (i.e. ROIs) within each contrast.

We examined the extracted beta values for normality by visually inspecting histograms of the data, checking for kurtosis and skewness values >1 , using Kolmogorov-Smirnov tests and looking for outliers as shown by SPSS's box and whisker plots. Across all regions, for both CBD and PBO and for both reward anticipation and feedback the data were normally distributed, so data were left unchanged.

[Insert Table 1]

In order to gain further support for either the null or alternative hypothesis for the effects of CBD on brain activity during reward anticipation and feedback, we also calculated scaled Jeffreys-Zellner-Siow (JZS) Bayes factors using an online calculator (<http://pcl.missouri.edu/bayesfactor>) (Buckingham et al., 2016; Lawn et al., 2018). We used a scaled-information prior of $r = 1$, which is the default value recommended (Rouder et al., 2009). For this analysis, a Bayes factor of >3 provides support for the null hypothesis (i.e. no difference in activation between CBD and placebo).

We conducted Pearson correlations between participant CBD plasma levels and their extracted beta values for each anticipate and feedback ROI, when they were on the CBD condition. We reduced the alpha value to 0.006 to account for multiple tests (i.e. ROIs) within each contrast.

Behavioural analyses

We conducted a Wilcoxon signed-rank test on the plasma CBD levels for CBD compared with PBO.

434 We conducted 2x2 repeated-measures analyses of variance (ANOVAs) for reaction time (RT)
435 and the proportion of hits, with within-subjects factors of drug (CBD, PBO) and trial-type (win,
436 neutral).

Results

Demographics

Of the 23 participants included in the analysis, there were 12 women and 11 men, with mean age 23.74 years (SD=4.2, range: 19-36). Participants' depression (BDI mean=2.2, SD=4.9, range: 0 to 11) and problematic alcohol use (AUDIT mean=2.2, SD=2.8, range: 0-7) levels were low. Participants had a mean WTAR raw score of 40.5 (SD=4.9, range: 33-49) and a mean BMI of 22.4 kg/m² (SD=3.5, range: 17.6-35.4).

Plasma CBD levels

Plasma CBD levels were higher on CBD (median=6.01ng/ml, interquartile range=4.89) than PBO (median=0, interquartile range=0) ($Z=3.296$, $p=0.001$).

MID behavioural results

For RT, there were main effects of drug ($F_{1, 22}=6.286$, $p=0.020$) and trial-type ($F_{1, 22}=15.841$, $p=0.001$), but there was not a significant interaction. Participants were faster to respond on win trials (mean=0.241s, SD=0.023) compared to neutral trials (mean=0.247s, SD=0.024). Participants were faster, overall, to respond under PBO (mean=0.241s, SD=0.024) compared to CBD (mean=0.247s, SD=0.024).

For proportion hit, there was a main effect of trial-type ($F_{1, 22}=43.776$, $p<0.001$), but no main effect of drug or interaction. Participants were more likely to hit on a win trial (mean=0.612, SD=0.079) compared to a neutral trial (mean=0.437, SD=0.072).

MID fMRI results

Movement did not exceed 3mm (our voxel size) in any direction for any of the participants. Mean and maximum movements were: x: mean=0.15mm (SD=0.50mm), max=0.50mm; y: mean=0.19mm (SD=0.12), max=0.50mm; z: mean=0.34mm (SD=0.32mm), max=2.00. Therefore we did not exclude any participants for excess movement.

Whole brain analyses

Effects of task (Table 2, Figure 2, Figure 3)

For the reward anticipation contrast, there was activation in three clusters, with peak activations in the insula bilaterally and the right paracingulate gyrus (Table 2). The right and left insula clusters extended into the right and left frontal operculum cortex, inferior frontal gyrus and orbitofrontal cortex. The paracingulate gyrus extended into the anterior cingulate gyrus, supplementary motor cortex and superior frontal gyrus (Figure 2).

For the reward feedback contrast, there was very widespread activation in two large clusters: one more posterior and one more anterior (Table 2; Figure 3). The posterior had a peak activation in the left occipital fusiform gyrus and extended into the bilateral cerebellum, intracalcarine gyrus, lingual gyrus, precuneus, inferior and middle temporal cortex, anterior and posterior lateral occipital gyrus, postcentral gyrus, posterior supramarginal gyrus, and hippocampus, amongst others. The anterior cluster had a peak activation in the left precentral gyrus and extended into the bilateral anterior cingulate cortex, paracingulate gyrus, superior and middle frontal gyrus, frontal pole, precentral gyrus, frontal medial cortex, and frontal operculum, amongst others. Activity was also observed in bilateral caudate, accumbens, thalamus and pallidum.

486 [Insert Table 2]

487 [Insert Figure 2]

488 [Insert Figure 3]

489

490 *Effects of the drug*

491 No significant clusters were found for CBD>PBO or PBO>CBD for either reward anticipation
492 or feedback.

493

494 *ROI analyses*

495 *Effects of task (Table 3)*

496 For reward anticipation, only the right insula was significantly activated ($t_{22}=3.87$, $p=0.001$)
497 during reward anticipation.

498

499 For reward feedback, the left ($t_{22}=3.31$, $p=0.003$) and right ($t_{22}=3.38$, $p=0.003$)
500 parahippocampal gyri, right caudate ($t_{22}=3.46$, $p=0.002$) and left nucleus accumbens ($t_{22}=4.02$,
501 $p=0.001$) were significantly activated during reward feedback.

502

503 [Insert Table 3]

504

505 *Effects of drug (Table 4)*

506 CBD did not differ from PBO in all of the ROIs during reward anticipation ($ps>0.1$).
507 Furthermore, all but one of the ROIs had a Bayes factor>3, in favour of there being no
508 difference between drug conditions.

509

510 CBD did not differ from PBO in all of the ROIs during reward feedback ($p>0.3$). Furthermore,
511 all the ROIs had Bayes factors >3 , in favour of there being no difference between drug
512 conditions.

513

514 [Insert Table 4]

515

516 Correlations

517 There were no significant correlations between plasma CBD levels and activation in any of the
518 ROIs during anticipation or feedback.

519

520

Discussion

We hypothesised that brain activity would be greater during reward anticipation and feedback following 600mg of oral CBD compared to PBO. However, this was not the case. We found no evidence that CBD affects the brain's response to reward anticipation or feedback. Furthermore, in pre-specified reward-related brain regions (Knutson and Greer, 2008), using Bayesian analyses, we found support for there being no difference in neural activity between CBD and PBO. Overall, we found no support for CBD affecting the neural correlates of reward anticipation and feedback or behavioural measures of motivation for reward in healthy volunteers.

Across both drug conditions, in the whole brain, our MID task elicited reward anticipation activation in the bilateral insula and paracingulate gyrus, extending into inferior frontal gyri and orbitofrontal cortex. In our ROI analysis, the right insula was significantly activated during reward anticipation. Reward feedback elicited extensive activity across anterior and posterior parts of the brain, including a range of reward-related brain regions. In our ROI analysis, the right caudate, left nucleus accumbens and bilateral parahippocampal gyri were activated during reward feedback. These analyses demonstrate that anticipation and feedback of reward produced activity in several expected brain regions. Further support that the task functioned adequately is that both reaction time and hit rate were significantly affected by trial type, such that participants were faster and more likely to successfully hit the target on win trials compared to neutral trials. Importantly, our plasma results demonstrate that the 600mg oral dose of CBD was absorbed.

In terms of behavioural outcomes, CBD led to longer reaction times compared to PBO overall. However, there was no interaction between drug and trial-type; CBD did not reduce reaction

times more for win trials than it did for neutral trials. Hence CBD did not affect our behavioural measure of motivation for reward; it simply increased reaction time, in general (i.e. comparably for both trial-types). This is somewhat surprising given previous research has not found CBD to affect reaction speed in general (Belgrave et al., 1979; Fusar-Poli et al., 2009; Hindocha et al., 2018).

Despite some existing evidence that CBD can impact reward function, we found null results for its effects on the neural correlates of reward anticipation and feedback. This absence of impact on reward circuitry, may contribute to the lack of reinforcing and abuse potential of CBD (Haney et al., 2016). To our knowledge, no previous study has examined the effects of CBD alone on brain activity associated with reward processing or motivation for reward. Previous studies have often investigated how inhaled CBD moderates THC's effects (Freeman et al., 2018; Lawn et al., 2016), which may have contributed to the discrepancy. Moreover, other studies have explored more complex components of reward function, including attentional bias toward drug pictures (Hindocha et al., 2018; Morgan et al., 2010). Other components of reward processing, including reward learning and subjective pleasure could also still be sensitive to a 600mg dose of oral CBD. CBD's acute effects on human behaviour and subjective experience are seemingly complicated and enigmatic (Bergamaschi et al., 2011; Fusar-Poli et al., 2009; Haney et al., 2016; Morgan et al., 2010). The same may well be true with regards to CBD's impacts on reward processing.

Furthermore, long-term daily administration of CBD, as delivered in clinical trials (Freeman et al., in press; Leweke et al., 2012; McGuire et al., 2018), could produce different effects on the neural correlates of reward anticipation and feedback. We only delivered a single oral 600mg dose in healthy volunteers. CBD likely has complex, variable dose-response functions on

diverse psychological outcomes (Zuardi et al., 2017). Nevertheless, experimental medicine approaches, such as this one, are needed to efficiently examine the acute effects of potentially therapeutic drugs in human models of psychiatric targets, where clinical trials are costly and protracted. Future research into CBD's effects on reward processing should expand the reward components assessed and utilise different doses. It should also examine consequences of repeated, long-term administration, which may allow for CBD levels to build up in the body and have greater impacts on receptor expression and endocannabinoid levels.

The present results leave open the intriguing possibility that CBD may only exert an effect on reward networks that have already been perturbed, for example in people with a drug addiction. CBD administration has been shown to modulate reward-related behaviours in animals when addiction is being modelled (Katsidoni et al., 2013; Parker et al., 2004; Ren et al., 2009; Schier et al., 2014; Viudez-Martínez et al., 2018). Moreover, behavioural evidence from human studies suggests that CBD can reduce the salience of drug-related cues in those with cannabis (Morgan et al., 2010) and nicotine (Hindocha et al., 2018) dependencies, and reduce drug cue-induced cravings in those addicted to heroin (Hurd et al., 2019). Additionally, a four-week treatment of CBD dose-dependently decreased cannabis use in a clinical trial of people with cannabis use disorder (Freeman et al., in press). In all of these studies, CBD attenuated atypical reward-related behaviours conferred by addiction, suggesting a restorative effect. Therefore, the null findings reported in the present study could have resulted from our sample of healthy volunteers. Future neuroimaging research should therefore administer CBD to participants thought to have perturbed reward systems, including those with addiction.

The reward system is thought to be critically involved in the emergence and/or maintenance of a variety of psychiatric disorders, including depression (Nestler and Carlezon, 2006; Whitton

et al., 2016), schizophrenia (Kapur et al., 2005; Whitton et al., 2016) and addiction (Berridge and Robinson, 2016; Goldstein and Volkow, 2011). If it emerges that CBD does have accepted therapeutic effects in these domains, further research will be needed to understand whether or not the mechanism is related to reward circuitry. Moreover, an improved understanding of CBD's pharmacological actions and their relative importance in treating reward-related psychological symptoms will be important in the development of cannabinoid-based psychiatric medicines. One possible avenue for future research would be to further understand and capitalize on CBD's agonism of the serotonin-1a receptor (Russo et al., 2005), in order to potentially disrupt addition and depressive symptoms.

Strengths and Limitations

Our study has a number of strengths. First and foremost, it was a double-blind, placebo-controlled experiment addressing a novel and important research question. Second, we utilised a well-validated fMRI task which elicited activity in many expected brain regions and appropriately affected behavioural performance. Third, CBD was absorbed into the bloodstream. Fourth, we conducted Bayesian analyses to provide support for null findings.

However, there are some limitations. Despite stimulating activity in many expected brain regions, the MID failed to produce anticipatory activation in the striatum, which is the region most commonly found to respond in this stage of the task (Oldham et al., 2018). Thus, CBD could theoretically affect striatal activity (Bhattacharyya et al., 2010) and we may have failed to detect it here. Finally, although CBD was absorbed relative to placebo, our plasma levels were lower than that seen in previous oral CBD studies (Haney et al., 2016; Millar et al., 2018). This may have been caused by our fasting participants, as a large, high-fat meal eaten before CBD administration can augment bioavailability four-fold (Taylor et al., 2018). Therefore, we

cannot exclude the possibility that if greater quantities of CBD had been absorbed, we may have observed different results. We also do not know whether 600mg is the optimal dose to manipulate reward processing, especially given CBD's potentially inverted U-shaped dose-response curve (Zuardi et al., 2017). Additionally, we did not control or account for female participants being in different stages of their menstrual cycle, which can affect psychopharmacological phenomena (Bolea-Alamanac et al., 2018).

Conclusion

To conclude, in healthy volunteers, a single, oral 600mg dose of CBD did not affect the neural correlates of reward anticipation and feedback, or behavioural measures of motivation for reward.

References

- Babalonis S, Haney M, Malcolm RJ, et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. *Drug and Alcohol Dependence* 172: 9–13. DOI: 10.1016/j.drugalcdep.2016.11.030.
- Balodis IM and Potenza MN (2015) Anticipatory Reward Processing in Addicted Populations: A Focus on the Monetary Incentive Delay Task. *Biological Psychiatry* 77(5): 434–444. DOI: 10.1016/j.biopsych.2014.08.020.
- Belgrave BE, Bird KD, Cheshier GB, et al. (1979) The effect of cannabidiol, alone and in combination with ethanol, on human performance. *Psychopharmacology* 64(2). Springer-Verlag: 243–246. DOI: 10.1007/BF00496070.
- Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. (2011) Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. *Neuropsychopharmacology* 36(6): 1219–1226. DOI: 10.1038/npp.2011.6.
- Bergamaschi MM, Helena Costa Queiroz R, Hortes M, et al. (2011) Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. *Neuropsychopharmacology* 36: 1219–1226. DOI: 10.1038/npp.2011.6.
- Berridge KC and Robinson TE (2016) Liking, Wanting and the Incentive-Sensitization Theory of Addiction. *The American psychologist* 71(8). NIH Public Access: 670. DOI: 10.1037/AMP0000059.
- Berridge KC, Robinson TE and Aldridge JW (2009) Dissecting components of reward: ‘liking’, ‘wanting’, and learning. *Current opinion in pharmacology* 9(1). NIH Public Access: 65–73. DOI: 10.1016/j.coph.2008.12.014.
- Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. (2010) Opposite Effects of Δ -9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. *Neuropsychopharmacology* 35(3): 764–774. DOI: 10.1038/npp.2009.184.

658 Bhattacharyya S, Falkenberg I, Martin-Santos R, et al. (2015) Cannabinoid Modulation of
 659 Functional Connectivity within Regions Processing Attentional Salience.
 660 *Neuropsychopharmacology* 40(6): 1343–1352. DOI: 10.1038/npp.2014.258.
 661 Bloomfield MAP, Ashok AH, Volkow ND, et al. (2016) The effects of Δ 9-
 662 tetrahydrocannabinol on the dopamine system. *Nature* 539(7629). Europe PMC
 663 Funders: 369–377. DOI: 10.1038/nature20153.
 664 Bolea-Alamanac B, Bailey SJ, Lovick TA, et al. (2018) Female psychopharmacology
 665 matters! Towards a sex-specific psychopharmacology. *Journal of Psychopharmacology*
 666 32(2). SAGE PublicationsSage UK: London, England: 125–133. DOI:
 667 10.1177/0269881117747578.
 668 Buckingham G, Goodale MA, White JA, et al. (2016) Equal-magnitude size-weight illusions
 669 experienced within and between object categories. *Journal of Vision* 16(3): 25. DOI:
 670 10.1167/16.3.25.
 671 Consroe P, Laguna J, Allender J, et al. (1991) Controlled clinical trial of cannabidiol in
 672 Huntington’s disease. *Pharmacology Biochemistry and Behavior* 40(3): 701–708. DOI:
 673 10.1016/0091-3057(91)90386-G.
 674 Curran HV, Freeman TP, Mokrysz C, et al. (2016) Keep off the grass? Cannabis, cognition
 675 and addiction. *Nature Reviews Neuroscience* 17(5): 293–306. DOI:
 676 10.1038/nrn.2016.28.
 677 Englund A, Morrison PD, Nottage J, et al. (2013) Cannabidiol inhibits THC-elicited paranoid
 678 symptoms and hippocampal-dependent memory impairment. *Journal of*
 679 *Psychopharmacology* 27(1): 19–27. DOI: 10.1177/0269881112460109.
 680 Eshel N and Roiser JP (2010) Reward and Punishment Processing in Depression. *Biological*
 681 *Psychiatry* 68(2): 118–124. DOI: 10.1016/j.biopsych.2010.01.027.
 682 Freeman TP, Pope RA, Wall MB, et al. (2018) Cannabis Dampens the Effects of Music in

Brain Regions Sensitive to Reward and Emotion. *International Journal of Neuropsychopharmacology* 21(1): 21–32. DOI: 10.1093/ijnp/pyx082.

Freeman TP, Groshkova T, Cunningham A, et al. (2019) Increasing potency and price of cannabis in Europe, 2006-16. *Addiction* 114(6): 1015–1023. DOI: 10.1111/add.14525.

Freeman TP, Hindocha C, Baio G, et al. (in press) Cannabidiol for the treatment of cannabis use disorder : Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial. *The Lancet Psychiatry*.

Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. (2009) Distinct Effects of Δ^9 -Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. *Archives of General Psychiatry* 66(1): 95. DOI: 10.1001/archgenpsychiatry.2008.519.

Gibbon M and Spitzer RL (1997) *Structured Clinical Interview for DSM-IV Axis II Personality Disorders, SCID-II*. American Psychiatric Press. Available at: https://books.google.co.uk/books?id=LMO3P8dMiPwC&printsec=frontcover&dq=structured+clinical+interview+dsm&hl=en&redir_esc=y (accessed 2 December 2019).

Ginsberg JP, Risser AH, Purisch AD, et al. (2003) BOOK AND TEST REVIEWS. *Applied Neuropsychology* 10(3): 182–190. DOI: 10.1207/S15324826AN1003_08.

Gold JM, Waltz JA, Prentice KJ, et al. (2008) Reward processing in schizophrenia: a deficit in the representation of value. *Schizophrenia bulletin* 34(5). Oxford University Press: 835–47. DOI: 10.1093/schbul/sbn068.

Goldstein RZ and Volkow ND (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. *Nature Reviews Neuroscience* 12(11): 652–669. DOI: 10.1038/nrn3119.

Grotenhermen F, Russo E and Zuardi AW (2017) Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and

708 Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004. *Cannabis and*
709 *cannabinoid research* 2(1). Mary Ann Liebert, Inc.: 1–4. DOI: 10.1089/can.2016.0036.

710 Haber SN and Knutson B (2010) The Reward Circuit: Linking Primate Anatomy and Human
711 Imaging. *Neuropsychopharmacology* 35(1): 4–26. DOI: 10.1038/npp.2009.129.

712 Haney M, Malcolm RJ, Babalonis S, et al. (2016) Oral Cannabidiol does not Alter the
713 Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
714 *Neuropsychopharmacology* 41(8). Nature Publishing Group: 1974. DOI:
715 10.1038/NPP.2015.367.

716 Hay GL, Baracz SJ, Everett NA, et al. (2018) Cannabidiol treatment reduces the motivation
717 to self-administer methamphetamine and methamphetamine-primed relapse in rats.
718 *Journal of Psychopharmacology* 32(12): 1369–1378. DOI: 10.1177/0269881118799954.

719 Heatherton TF, Kozlowski LT, Frecker RC, et al. (1991) The Fagerstrom Test for Nicotine
720 Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Addiction* 86(9):
721 1119–1127. DOI: 10.1111/j.1360-0443.1991.tb01879.x.

722 Hindocha C, Freeman TP, Schafer G, et al. (2015) Acute effects of delta-9-
723 tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition:
724 A randomised, double-blind, placebo-controlled study in cannabis users. *European*
725 *Neuropsychopharmacology* 25(3): 325–334. DOI: 10.1016/j.euroneuro.2014.11.014.

726 Hindocha C, Freeman Tom P., Grabski M, et al. (2018) Cannabidiol reverses attentional bias
727 to cigarette cues in a human experimental model of tobacco withdrawal. *Addiction*
728 113(9). Wiley-Blackwell: 1696–1705. DOI: 10.1111/add.14243.

729 Hindocha C, Freeman Tom P, Grabski M, et al. (2018) Cannabidiol reverses attentional bias
730 to cigarette cues in a human experimental model of tobacco withdrawal. DOI:
731 10.1111/add.14243.

732 Hurd YL, Spriggs S, Alishayev J, et al. (2019) Cannabidiol for the Reduction of Cue-Induced

733 Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A
 734 Double-Blind Randomized Placebo-Controlled Trial. *American Journal of Psychiatry*
 735 176(11): 911–922. DOI: 10.1176/appi.ajp.2019.18101191.

736 Husain M and Roiser JP (2018) Neuroscience of apathy and anhedonia: a transdiagnostic
 737 approach. *Nature Reviews Neuroscience* 19(8). Nature Publishing Group: 470–484.
 738 DOI: 10.1038/s41583-018-0029-9.

739 Insel TR (2010) Rethinking schizophrenia. *Nature* 468(7321): 187–193. DOI:
 740 10.1038/nature09552.

741 Jansma JM, van Hell HH, Vanderschuren LJMJ, et al. (2013) THC reduces the anticipatory
 742 nucleus accumbens response to reward in subjects with a nicotine addiction.
 743 *Translational psychiatry* 3(2). Nature Publishing Group: e234. DOI: 10.1038/tp.2013.6.

744 Jenkinson M, Beckmann CF, Behrens TEJ, et al. (2012) FSL. *NeuroImage* 62(2): 782–790.
 745 DOI: 10.1016/j.neuroimage.2011.09.015.

746 Juckel G, Schlagenhauf F, Koslowski M, et al. (2006) Dysfunction of ventral striatal reward
 747 prediction in schizophrenia. *NeuroImage* 29(2): 409–416. DOI:
 748 10.1016/j.neuroimage.2005.07.051.

749 Kapur S, Mizrahi R and Li M (2005) From dopamine to salience to psychosis—linking
 750 biology, pharmacology and phenomenology of psychosis. *Schizophrenia Research*
 751 79(1): 59–68. DOI: 10.1016/j.schres.2005.01.003.

752 Katsidoni V, Anagnostou I and Panagis G (2013) Cannabidiol inhibits the reward-facilitating
 753 effect of morphine: involvement of 5-HT_{1A} receptors in the dorsal raphe nucleus.
 754 *Addiction Biology* 18(2): 286–296. DOI: 10.1111/j.1369-1600.2012.00483.x.

755 Khan R, Naveed S, Mian N, et al. (2020) The therapeutic role of Cannabidiol in mental
 756 health: a systematic review. *Journal of Cannabis Research* 2(1). BioMed Central: 2.
 757 DOI: 10.1186/s42238-019-0012-y.

758 Knutson B and Greer SM (2008) Anticipatory affect: neural correlates and consequences for
 759 choice. *Philosophical transactions of the Royal Society of London. Series B, Biological*
 760 *sciences* 363(1511). The Royal Society: 3771–86. DOI: 10.1098/rstb.2008.0155.

761 Knutson B, Westdorp A, Kaiser E, et al. (2000) FMRI Visualization of Brain Activity during
 762 a Monetary Incentive Delay Task. *NeuroImage* 12(1): 20–27. DOI:
 763 10.1006/nimg.2000.0593.

764 Knutson B, Adams CM, Fong GW, et al. (2001) Anticipation of increasing monetary reward
 765 selectively recruits nucleus accumbens. *The Journal of neuroscience : the official*
 766 *journal of the Society for Neuroscience* 21(16). Society for Neuroscience: RC159. DOI:
 767 10.1523/JNEUROSCI.21-16-J0002.2001.

768 Knutson B, Bhanji JP, Cooney RE, et al. (2008) Neural Responses to Monetary Incentives in
 769 Major Depression. *Biological Psychiatry* 63(7): 686–692. DOI:
 770 10.1016/j.biopsych.2007.07.023.

771 Knutson B, Wimmer GE, Kuhnen CM, et al. (2008) Nucleus accumbens activation mediates
 772 the influence of reward cues on financial risk taking. *NeuroReport* 19(5): 509–513. DOI:
 773 10.1097/WNR.0b013e3282f85c01.

774 Lawn W, Freeman TP, Pope RA, et al. (2016) Acute and chronic effects of cannabinoids on
 775 effort-related decision-making and reward learning: an evaluation of the cannabis
 776 ‘amotivational’ hypotheses. *Psychopharmacology* 233(19–20): 3537–3552. DOI:
 777 10.1007/s00213-016-4383-x.

778 Lawn W, Freeman TP, East Msc K, et al. (2018) The Acute Effects of a Dopamine D3
 779 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional
 780 Cigarette Smokers. *Nicotine & Tobacco Research*: 800–809. DOI: 10.1093/ntr/ntx159.

781 Leweke FM, Piomelli D, Pahlisch F, et al. (2012) Cannabidiol enhances anandamide
 782 signaling and alleviates psychotic symptoms of schizophrenia. *Translational psychiatry*

783 2(3). Nature Publishing Group: e94. DOI: 10.1038/tp.2012.15.

784 Martin-Santos R, A. Crippa J, Batalla A, et al. (2012) Acute Effects of a Single, Oral dose of
 785 Δ^9 -tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy
 786 Volunteers. *Current Pharmaceutical Design* 18(32): 4966–4979. DOI:
 787 10.2174/138161212802884780.

788 McGuire P, Robson P, Cubala WJ, et al. (2018) Cannabidiol (CBD) as an Adjunctive
 789 Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. *American*
 790 *Journal of Psychiatry* 175(3): 225–231. DOI: 10.1176/appi.ajp.2017.17030325.

791 Millar SA, Stone NL, Yates AS, et al. (2018) A Systematic Review on the Pharmacokinetics
 792 of Cannabidiol in Humans. *Frontiers in Pharmacology* 9: 1365. DOI:
 793 10.3389/fphar.2018.01365.

794 Morgan Celia Ja, Freeman TP, Schafer GL, et al. (2010) Cannabidiol Attenuates the
 795 Appetitive Effects of Δ^9 -Tetrahydrocannabinol in Humans Smoking Their Chosen
 796 Cannabis. *Neuropsychopharmacology* 35: 1879–1885. DOI: 10.1038/npp.2010.58.

797 Morgan Celia JA, Freeman TP, Schafer GL, et al. (2010) Cannabidiol Attenuates the
 798 Appetitive Effects of Δ^9 -Tetrahydrocannabinol in Humans Smoking Their Chosen
 799 Cannabis. *Neuropsychopharmacology* 35(9). Nature Publishing Group: 1879. DOI:
 800 10.1038/NPP.2010.58.

801 Morgan PJ, Barnett LM, Cliff DP, et al. (2013) Fundamental Movement Skill Interventions in
 802 Youth: A Systematic Review and Meta-analysis. *PEDIATRICS* 132(5): e1361–e1383.
 803 DOI: 10.1542/peds.2013-1167.

804 Nestler EJ and Carlezon WA (2006) The Mesolimbic Dopamine Reward Circuit in
 805 Depression. *Biological Psychiatry* 59(12): 1151–1159. DOI:
 806 10.1016/j.biopsych.2005.09.018.

807 Oldham S, Murawski C, Fornito A, et al. (2018) The anticipation and outcome phases of

808 reward and loss processing: A neuroimaging meta-analysis of the monetary incentive
809 delay task. *Human Brain Mapping* 39(8). John Wiley & Sons, Ltd: 3398–3418. DOI:
810 10.1002/hbm.24184.

811 Parker LA, Page , Robert B, et al. (2004) Effect of low doses of D 9-tetrahydrocannabinol
812 and cannabidiol on the extinction of cocaine-induced and amphetamine-induced
813 conditioned place preference learning in rats. *Psychopharmacology* 175: 360–366. DOI:
814 10.1007/s00213-004-1825-7.

815 Parsons LH and Hurd YL (2015) Endocannabinoid signalling in reward and addiction.
816 *Nature Reviews Neuroscience* 16(10): 579–594. DOI: 10.1038/nrn4004.

817 Pertwee RG (2008) The diverse CB 1 and CB 2 receptor pharmacology of three plant
818 cannabinoids: D 9-tetrahydrocannabinol, cannabidiol and D 9-tetrahydrocannabivarin.
819 *British Journal of Pharmacology* 153: 199–215. DOI: 10.1038/sj.bjp.0707442.

820 Ren Y, Whittard J, Higuera-Matas A, et al. (2009) Cannabidiol, a nonpsychotropic
821 component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete
822 mesolimbic neuronal disturbances. *The Journal of neuroscience : the official journal of*
823 *the Society for Neuroscience* 29(47). Society for Neuroscience: 14764–9. DOI:
824 10.1523/JNEUROSCI.4291-09.2009.

825 Renard J, Szkudlarek HJ, Kramar CP, et al. (2017) Adolescent THC Exposure Causes
826 Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of
827 Sub-Cortical Dopamine Function. *Scientific Reports* 7(1). Nature Publishing Group:
828 11420. DOI: 10.1038/s41598-017-11645-8.

829 Rouder JN, Speckman PL, Sun D, et al. (2009) Bayesian t tests for accepting and rejecting
830 the null hypothesis. *Psychonomic Bulletin & Review* 16(2). Springer-Verlag: 225–237.
831 DOI: 10.3758/PBR.16.2.225.

832 Russo EB, Burnett A, Hall B, et al. (2005) Agonistic Properties of Cannabidiol at 5-HT1a

833 Receptors. *Neurochemical Research* 30(8): 1037-1043. DOI: 10.1007/s11064-005-6978-
834 1

835 Saunders JB, Aasland OG, Babor TF, et al. (1993) Development of the Alcohol Use
836 Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection
837 of Persons with Harmful Alcohol Consumption-II. *Addiction* 88(6): 791–804. DOI:
838 10.1111/j.1360-0443.1993.tb02093.x.

839 Schier A, Ribeiro N, Coutinho D, et al. (2014) Antidepressant-Like and Anxiolytic-Like
840 Effects of Cannabidiol: A Chemical Compound of Cannabis sativa. *CNS & Neurological
841 Disorders - Drug Targets* 13(6): 953–960. DOI:
842 10.2174/1871527313666140612114838.

843 Schott BH, Minuzzi L, Krebs RM, et al. (2008) Mesolimbic Functional Magnetic Resonance
844 Imaging Activations during Reward Anticipation Correlate with Reward-Related
845 Ventral Striatal Dopamine Release. *Journal of Neuroscience* 28(52): 14311–14319.
846 DOI: 10.1523/JNEUROSCI.2058-08.2008.

847 Solinas M, Thiriet N, Rawas R El, et al. (2009) Environmental Enrichment During Early
848 Stages of Life Reduces the Behavioral, Neurochemical, and Molecular Effects of
849 Cocaine. *Neuropsychopharmacology* 34(5): 1102–1111. DOI: 10.1038/npp.2008.51.

850 Strauss GP, Horan WP, Kirkpatrick B, et al. (2013) Deconstructing negative symptoms of
851 schizophrenia: Avolition–apathy and diminished expression clusters predict clinical
852 presentation and functional outcome. *Journal of Psychiatric Research* 47(6): 783–790.
853 DOI: 10.1016/j.jpsychires.2013.01.015.

854 Taylor L, Gidal B, Blakey G, et al. (2018) A Phase I, Randomized, Double-Blind, Placebo-
855 Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety,
856 Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
857 *CNS Drugs* 32(11): 1053–1067. DOI: 10.1007/s40263-018-0578-5.

858 van Hell HH, Jager G, Bossong MG, et al. (2012) Involvement of the endocannabinoid
 859 system in reward processing in the human brain. *Psychopharmacology* 219(4). Springer:
 860 981–990. DOI: 10.1007/s00213-011-2428-8.

861 Viudez-Martínez A, García-Gutiérrez MS, Navarrón CM, et al. (2018) Cannabidiol reduces
 862 ethanol consumption, motivation and relapse in mice. *Addiction Biology* 23(1): 154–
 863 164. DOI: 10.1111/adb.12495.

864 Whitton AE, Treadway MT and Pizzagalli DA (2015) Reward processing dysfunction in
 865 major depression, bipolar disorder and schizophrenia. *Current Opinion in Psychiatry*
 866 28(1): 7–12. DOI: 10.1097/YCO.0000000000000122.

867 Whitton AE, Kakani P, Foti D, et al. (2016) Blunted neural responses to reward in remitted
 868 major depression: A high-density event-related potential study. *Biological psychiatry*.
 869 *Cognitive neuroscience and neuroimaging* 1(1). NIH Public Access: 87–95. DOI:
 870 10.1016/j.bpsc.2015.09.007.

871 Zuardi AW, Cosme RA, Graeff FG, et al. (1993) Effects of ipsapirone and cannabidiol on
 872 human experimental anxiety. *Journal of Psychopharmacology* 7(1_suppl): 82–88. DOI:
 873 10.1177/026988119300700112.

874 Zuardi AW, Rodrigues NP, Silva AL, et al. (2017) Inverted U-Shaped Dose-Response Curve
 875 of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. *Frontiers*
 876 *in Pharmacology* 8: 259. DOI: 10.3389/fphar.2017.00259.

877